What is RevBio?
Headquartered in Lowell, Massachusetts, RevBio is a pioneering biotechnology firm specializing in the development of advanced bone adhesive platforms. By reverse-engineering the mineral-organic compounds found in the Sandcastle Worm, the company has created a patented bioadhesive designed to revolutionize orthopedic and dental surgical procedures. With a robust foundation built on over 10 research grants and a growing portfolio of intellectual property, RevBio is currently transitioning from a research-intensive startup to a clinical-stage enterprise. The company's current focus remains on its first-in-human clinical trials, which serve as a critical milestone in validating the safety and efficacy of its biomimetic materials in real-world medical applications.
How much funding has RevBio raised?
RevBio has raised a total of $10M across 1 funding round:
Debt
$10M
Debt (2025): $10M, investors not publicly disclosed
Key Investors in RevBio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for RevBio?
With the recent capital deployment, RevBio is positioned to aggressively pursue its clinical roadmap and regulatory milestones. The strategic focus will likely shift toward expanding its platform of bone repair applications and strengthening its manufacturing capabilities to meet potential market demand. As the company navigates the complexities of the medical device landscape, the integration of its bioadhesive technology into standard surgical workflows will be the primary driver of long-term value creation. Investors and industry stakeholders will be closely monitoring the outcomes of the ongoing clinical trials, as positive data could catalyze further institutional interest and facilitate a broader market entry for this disruptive orthopedic solution.
See full RevBio company page
